Xeris Biopharma (NASDAQ:XERS) Stock Keeps “Neutral” Rating at Piper Sandler

Xeris Biopharma (NASDAQ:XERS)‘s stock had its “neutral” rating reiterated by stock analysts at Piper Sandler in a research report issued on Friday, Benzinga reports. They presently have a $12.00 target price on the stock, up from their previous target price of $8.00. Piper Sandler‘s price objective would indicate a potential downside of 13.97% from the company’s current price.

A number of other research analysts have also recently commented on XERS. HC Wainwright increased their price target on shares of Xeris Biopharma from $10.00 to $18.00 and gave the company a “buy” rating in a research report on Friday. Leerink Partners upped their price objective on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a research note on Thursday, September 10th. Barclays increased their target price on shares of Xeris Biopharma from $12.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, October 6th. Wall Street Zen upgraded shares of Xeris Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Finally, Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $15.60.

Xeris Biopharma Price Performance

XERS opened at $13.95 on Friday. The stock has a 50-day moving average price of $9.49 and a 200-day moving average price of $7.58. Xeris Biopharma has a 12-month low of $5.25 and a 12-month high of $13.74. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00. The stock has a market capitalization of $2.54 billion, a P/E ratio of -127.09 and a beta of 0.61.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.03 by $0.03. The firm had revenue of $107.23 million for the quarter, compared to analyst estimates of $101.68 million. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. Equities analysts predict that Xeris Biopharma will post 0.07 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Steven Pieper sold 5,000 shares of Xeris Biopharma stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total value of $51,150.00. Following the transaction, the insider directly owned 1,346,053 shares of the company’s stock, valued at $13,770,122.19. The trade was a 0.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 25,000 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total transaction of $255,750.00. Following the sale, the insider owned 1,086,130 shares of the company’s stock, valued at $11,111,109.90. This represents a 2.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 148,332 shares of company stock valued at $1,409,221 in the last ninety days. Company insiders own 4.35% of the company’s stock.

Institutional Investors Weigh In On Xeris Biopharma

A number of large investors have recently added to or reduced their stakes in XERS. BlackRock Inc. purchased a new position in shares of Xeris Biopharma in the second quarter valued at about $115,042,000. Legal & General Group Plc bought a new position in shares of Xeris Biopharma during the second quarter valued at about $15,941,000. Parkman Healthcare Partners LLC purchased a new stake in shares of Xeris Biopharma during the second quarter worth about $14,316,000. Bank of America Corp DE purchased a new stake in shares of Xeris Biopharma during the second quarter worth about $11,065,000. Finally, Vilga Financial Planning LLC purchased a new stake in shares of Xeris Biopharma during the third quarter worth about $10,134,000. Institutional investors own 42.75% of the company’s stock.

Key Stories Impacting Xeris Biopharma

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q3 results topped expectations: Xeris reported earnings of $0.06 per share versus consensus of $0.03, while revenue of $107.23 million exceeded the $101.68 million estimate. The results helped drive the positive stock response. Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
• Positive Sentiment: Stronger Recorlev sales outlook: CEO John Shannon reportedly sees Recorlev approaching $1 billion in annual sales three to four years earlier than previously expected. Xeris also updated its FY 2030 earnings guidance, though the supplied report does not provide the revised figures. Xeris CEO Sees Recorlev Nearing $1B in Annual Sales Earlier Than Expected
• Positive Sentiment: Analyst raised target: HC Wainwright lifted its price target from $10 to $18 and maintained a Buy rating, signaling confidence in further upside. HC Wainwright recommendations
• Negative Sentiment: Insider sales: Several executives sold shares at $10.23, including Steven Pieper, Kevin McCulloch and Beth Hecht. The transactions were made under pre-arranged 10b5-1 plans, and each retained substantial holdings, which may temper the negative signal. Xeris Biopharma Insider Trading

Xeris Biopharma Company Profile

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.